Readily available biomarkers predict poor survival in metastatic pancreatic cancer.
Strijker M, van Veldhuisen E, van der Geest LG, Busch OR, Bijlsma MF, Haj Mohammad N, Homs MY, van Hooft JE, Verheij J, de Vos-Geelen J, Wilmink JW, Steyerberg WEW, Besselink MG, van Laarhoven HW; Dutch Pancreatic Cancer Group.
Strijker M, et al. Among authors: haj mohammad n.
Biomarkers. 2021 Jun;26(4):325-334. doi: 10.1080/1354750X.2021.1893814. Epub 2021 Mar 21.
Biomarkers. 2021.
PMID: 33663300